← ANALYST RATINGS · TIPRANKS
SI-Bone (SIBN): analyst forecast and price target
Analyst consensus
Strong Buy3 Buy0 Hold0 Sell
Ratings of 3 analysts in the last 3 months · top analysts only12-month forecast
Based on 3 price targets given in the last 3 months, the average target is $22.50, the highest $25.00, the lowest $20.00. The average is +14.3% from the last price of $19.68.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Caitlin Roberts★★★★★★★★★★#1832 · hits 65% · avg +14.7% | Canaccord Genuity | $27.00 | Buy | +37.2% | Reiterated | 14.10.26on TipRanks Oct 15 07:30 | 0.0%next day +2.0% | ↗ |
| Richard Newitter★★★★★★★★★★#1772 · hits 48% · avg +6.6% | Truist Financial | $23.00 → $25.00+8.7% | Buy | +27.0% | Reiterated | 14.10.26on TipRanks 08:35 | 0.0%next day +2.0% | ↗ |
| AI xAi Medical - DevicesxAI Grok-3 | TipRanks - xAI | $22.00 → $19.50−11.4% | Hold | −0.9% | Downgrade | 12.09.26on TipRanks Sep 11 22:05 | — | |
| AI DeepSeek Medical - DevicesDeepSeek R1-0528 | TipRanks - DeepSeek | $22.00 → $19.00−13.6% | Hold | −3.5% | Downgrade | 12.09.26on TipRanks Sep 11 22:05 | — | |
| AI OpenAI Medical - DevicesOpenAI 4o | TipRanks - OpenAI | $21.50 → $19.00−11.6% | Hold | −3.5% | Reiterated | 12.09.26on TipRanks Sep 11 22:05 | — | |
| AI Anthropic Medical - DevicesAnthropic Opus-4.1 | TipRanks - Anthropic | $21.00 → $19.00−9.5% | Hold | −3.5% | Reiterated | 12.09.26on TipRanks Sep 11 22:05 | — | |
| AI Google Medical - DevicesGemini 2.5Pro | TipRanks - Google | $22.50 → $20.00−11.1% | Hold | +1.6% | Downgrade | 12.09.26on TipRanks Sep 11 22:05 | — | |
| AI PerPlexity Medical - DevicesPerPlexity SonarPro | TipRanks - PerPlexity | $22.00 → $20.00−9.1% | Hold | +1.6% | Downgrade | 12.09.26on TipRanks Sep 11 22:05 | — | |
| Travis Steed★★★★★★★★★★#3596 · hits 53% · avg +3.0% | Bank of America Securities | — | Buy | — | Reiterated | 04.08.26on TipRanks 11:38 | −1.9%next day −2.0% · 5 days +2.1% | ↗ |
| Patrick Wood★★★★★★★★★★#10768 · hits 50% · avg −2.1% | UBS | $24.00 → $25.00+4.2% | Buy | +27.0% | Reiterated | 04.08.26on TipRanks 08:26 | −1.9%next day −2.0% · 5 days +2.1% | ↗ |
| Matthew O'Brien★★★★★★★★★★#12031 · hits 41% · avg −4.5% | Piper Sandler | $25.00 | Buy | +27.0% | Reiterated | 04.08.26on TipRanks 07:51 | −1.9%next day −2.0% · 5 days +2.1% | ↗ |
| David Saxon★★★★★★★★★★#6662 · hits 38% · avg +0.8% | Needham | $27.00 | Buy | +37.2% | Reiterated | 04.08.26on TipRanks 07:51 | −1.9%next day −2.0% · 5 days +2.1% | ↗ |
| Mathew Blackman★★★★★★★★★★#2177 · hits 49% · avg +9.2% | TD Cowen | $18.00 → $20.00+11.1% | Buy | +1.6% | Assigned | 04.08.26on TipRanks Aug 3 21:30 | −1.9%next day −2.0% · 5 days +2.1% | ↗ |
| Rong Li★★★★★★★★★★#8516 · hits 50% · avg +3.7% | Jefferies | $28.00 | Buy | +42.3% | Reiterated | 09.01.26on TipRanks 11:00 | −2.8%next day −12.7% · 5 days −16.5% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering SI-Bone
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $24.50 at a price of $18.80 (+30.3%); now: $24.83 at $19.68 (+26.2%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 0 | 0 | 0 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 09.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.13 (from $-0.17 to $-0.07). Last quarter: $-0.09.
Sales
Next quarter’s sales estimate — $55M (from $55M to $56M). Last quarter: $56M.
Best top-analyst consensus in the sector · Healthcare
About SI-Bone
- CEO: Laura A. Francis
- Employees: 376
- 471 El Camino Real, Santa Clara, CA, 95050, US
- si-bone.com
SI-BONE, Inc. is a medical technology company that develops and markets specialized implantable solutions for musculoskeletal conditions affecting the sacropelvic region. These devices are utilized across the United States and internationally. Its flagship product, iFuse, is a minimally invasive surgical implant system designed to address a range of indications, including sacroiliac joint dysfunction and degeneration, adult spinal deformities, and traumatic fractures of the pelvic ring. Beyond iFuse, the company offers advanced iterations like iFuse-3D. This titanium implant retains the distinctive triangular cross-section of the original iFuse but incorporates a proprietary 3D-printed porous surface and a fenestrated design. Another offering is iFuse-TORQ, a series of 3D-printed threaded implants. These are specifically engineered for treating pelvic fractures and facilitating minimally invasive sacroiliac joint fusion procedures. SI-BONE distributes its products primarily through a dedicated direct sales force, complemented by a network of independent distributors. Established in 2008, the company maintains its corporate headquarters in Santa Clara, California.
Data from the stock’s TipRanks forecast page, read 104 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗